PRODUCT MONOGRAPH

20% ProSol

Amino Acid Injection 20% w/v

Solution for Infusion

Intravenous Nutritive Supplement

Pharmacy Bulk Pack (Not for direct infusion)

Baxter Corporation
Mississauga, Ontario, Canada
L5N 0C2

Date of Revision: September 3, 2015

Submission Control No: 185156

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION 3
SUMMARY PRODUCT INFORMATION 3
INDICATIONS AND CLINICAL USE 3
CONTRAINDICATIONS 3
WARNINGS AND PRECAUTIONS 4
ADVERSE REACTIONS 8
DRUG INTERACTIONS 9
DOSAGE AND ADMINISTRATION 9
OVERDOSAGE 12
ACTION AND CLINICAL PHARMACOLOGY 13
STORAGE AND STABILITY 13
DOSAGE FORMS, COMPOSITION AND PACKAGING 13
PART II: SCIENTIFIC INFORMATION 15
PHARMACEUTICAL INFORMATION 15
CLINICAL TRIALS 17
DETAILED PHARMACOLOGY 17
TOXICOLOGY 17
REFERENCES 18
PART III: CONSUMER INFORMATION 19

20% ProSol

Amino Acid Injection 20% w/v

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Intravenous	Solution for Infusion (Not for direct infusion) Amino Acid Injection 20% w/v	None of the nonmedicinal ingredients are clinically relevant. *For a complete listing see Dosage Forms, Composition and Packaging section.*

INDICATIONS AND CLINICAL USE

20% ProSol (Amino Acid Injection 20% w/v) when administered with a source of energy is indicated as a source of amino acid in the treatment of negative nitrogen balance in patients where:
(1) the alimentary tract cannot or should not be used.
(2) gastrointestinal absorption of amino acids is impaired, or
(3) metabolic requirements for protein are substantially increased, as with extensive burns.

Geriatrics:
In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.

Pediatrics:
There have been no studies performed by Baxter Healthcare Corporation in the pediatric population. See **Special Populations, Pediatrics** section regarding monitoring for hyperammonemia in pediatric patients.

CONTRAINDICATIONS

The use of 20% ProSol (Amino Acid Injection 20% w/v) is contraindicated in the following populations/situations:

- Known hypersensitivity to any of the substances of the solutions and /or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the Product Monograph.
- Patients with severe liver failure or hepatic coma.
- Patients with acute renal failure and without undergoing renal replacement therapy.
- Congenital abnormality of amino acid metabolism.

WARNINGS AND PRECAUTIONS

General

- The contents of the products are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion.
- Proper administration of a ProSol product requires a knowledge of fluid and electrolyte balance, nutritional status, nature of the disease, vital organ function as well as clinical expertise in prescribing PN regimens and recognition and treatment of the complications which may occur.
- It is essential to provide adequate calories concurrently if parenterally administered amino acids are to be retained by the body and utilized for protein synthesis.
- Severe water and electrolyte disorders, severe fluid overload states, and severe metabolic disorders should be corrected before starting the infusion.
- Do not administer unless solution is clear.
- A slight yellow color does not alter the quality and efficacy of this product.

Exercise caution to ensure that precipitates are not formed in any parenteral nutrient products since precipitates may result in life-threatening clinical outcomes (see Respiratory subsection and **ADVERSE REACTIONS** section).

If additional substances (other PN solution, additional electrolytes and/or other additives) are to be admixed with ProSol product, compatibility of the substances with the product must be evaluated to ensure that the final solution is stable and free of precipitates (see **DOSAGE AND ADMINISTRATION** section).

During infusion, the infusion set and catheter should also periodically be checked for precipitates. If precipitates (particular matters) are observed, infusion MUST be immediately stopped and medical evaluation is initiated.

Aseptic techniques are required when additives are added as nutrients in the products may support growth of microorganisms.

The administration of 20% ProSol (Amino Acid Injection 20% w/v) as part of total parenteral nutrition (TPN) with large volumes of hyperosmotic fluids requires periodic monitoring of the patient for signs of hyperosmolarity, hyperglycemia, glycosuria and hypertriglyceridemia.

During prolonged parenteral nutrition with amino acid and dextrose solutions, essential fatty acid deficiency syndrome may develop but may not be clinically apparent. Early demonstration of this condition can only be accomplished by analysis of plasma lipids. The syndrome may be prevented or corrected by appropriate treatment with intravenous lipid emulsions.

Administration of amino acid solutions and other nutrients via central or peripheral venous catheter may be associated with complications which can be prevented or minimized by careful attention to all aspects of the procedure. This includes attention to solution preparation, administration, and patient monitoring. It is essential that a carefully prepared protocol, based on current medical practices, be followed, preferably by an experienced team.

Infection and sepsis may occur as a result of the use of intravenous catheters to administer parenteral formulations, poor maintenance of catheters or contaminated solutions.

Immunosuppression and other factors such as hyperglycemia, malnutrition and/or their underlying disease state may predispose patients to infectious complications.

Careful symptomatic and laboratory monitoring for fever/chills, leukocytosis, technical complications with the access device, and hyperglycemia can help recognize early infections.

The occurrence of septic complications can be decreased with heightened emphasis on aseptic technique in catheter placement, maintenance, as well as aseptic technique in nutritional formula preparation.

Refeeding severely undernourished patients may result in the refeeding syndrome that is characterized by the shift of potassium, phosphorus, and magnesium intracellularly as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. Careful monitoring and slowly increasing nutrient intakes while avoiding overfeeding can prevent these complications.

Hypertonic infusion solutions may cause irritation of the vein when administered into a peripheral vein (see **ADVERSE REACTIONS, Post-Marketing Adverse Reactions**).

During protein sparing therapy in the absence of supporting carbohydrate metabolism, an accumulation of ketone bodies in the blood often occurs. Correction of ketonemia usually can be accomplished by administration of carbohydrates.

20% ProSol (Amino Acid Injection 20% w/v) must not be infused through the same tubing with blood or blood components unless there is documentation that it is safe.

Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.

Cardiovascular

Use with caution in patients with pulmonary edema or heart failure. Fluid status should be closely monitored.

Endocrine and Metabolism

Metabolic complications may occur if the nutrient intake is not adapted to the patient's requirements, or the metabolic capacity of any given dietary component is not accurately assessed. Adverse metabolic effects may arise from administration of inadequate or excessive nutrients or from inappropriate composition of an admixture for a particular patient's needs.

When administered as component of parenteral nutrition, the following metabolic complications have been reported: metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia and glycosuria, osmotic diuresis and dehydration, rebound hypoglycemia, elevated liver enzymes,

hypo and hypervitaminosis, electrolyte imbalances, and hyperammonemia. Frequent clinical evaluation and laboratory determinations are necessary, especially during the first few days of therapy, to prevent or minimize these conditions.

Depending on extent and etiology, hyperammonemia may require immediate intervention. Should symptoms of hyperammonemia develop, administration should be discontinued and the patient's clinical status re-evaluated.

Hyperammonemia is of special significance in newborns and infants. In some patients this may indicate the presence of a congenital disorder of amino acid metabolism or hepatic insufficiency. It is essential that blood ammonia be measured frequently in newborns and infants.

Blood and urine glucose should be monitored regularly.
In patients with myocardial infraction, infusion of amino acids should always be accompanied by dextrose since in anoxia, fatty acids cannot be properly utilized by myocardium.

Special care must be taken when giving hypertonic dextrose to patients with impaired glucose tolerance such as diabetics or prediabetics and uremic patients, especially when the latter are receiving peritoneal dialysis. To prevent severe hyperglycemia in such patients, insulin may be required.

When ProSol is administered with dextrose, to reduce the risk of hyperglycemia-associated complications, the infusion rate must be adjusted and/or insulin administered if blood glucose levels exceed levels considered acceptable for the individual patient.

Handling of glucose load is also frequently impaired in patients with liver failure.

Hepatic/Biliary/Pancreatic
Administration of amino acid solutions at excessive rates or to patients with hepatic insufficiency may result in plasma amino acid imbalances, hyperammonemia, stupor and coma.

Parenteral nutrition in general as well as amino acid solutions should be used with caution in patients with preexisting liver disease or liver insufficiency. Liver function parameters should be closely monitored in these patients, and they should be monitored for possible symptoms of hyperammonemia. Should symptoms of hyperammonemia develop, amino acid administration should be discontinued and the patient's clinical status re-evaluated.

Hepatobiliary disorders including cholestasis, hepatic steatosis, fibrosis and cirrhosis, possibly leading to hepatic failure, as well as cholecystitis and cholelithiasis are known to develop in some patients on parenteral nutrition. The etiology of these disorders is thought to be multifactorial and may differ between patients. Patients developing abnormal laboratory parameters or other signs of hepatobiliary disorders should be assessed early by a clinician knowledgeable in liver diseases in order to identify possible causative and contributory factors, and possible therapeutic and prophylactic interventions.

Immune
Anaphylactic/anaphylactoid reactions and other hypersensitivity/infusion reactions have been reported with amino acid solutions administered as a component of parenteral nutrition (see Section 4.8). The infusion must be stopped immediately if any signs or symptoms of a reaction develop.

Renal
Use with caution in patients with renal insufficiency. Fluid and electrolyte status should be closely monitored for water and/or electrolyte retention and managed appropriately.

Azotemia has been reported with parenteral administration of solutions containing amino acids, and may occur in particular in the presence of renal impairment.

Respiratory
Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving parenteral nutrition. In some cases, fatal outcomes have occurred. Excessive addition of calcium and phosphate increases the risk of the formation of calcium phosphate precipitates. Precipitates have been reported even in the absence of phosphate salt in the solution. Precipitation distal to the in-line filter and suspected in vivo precipitate formation has also been reported.

If signs of pulmonary distress occur, the infusion should be stopped and medical evaluation initiated.

For complete nutritional support, TPN regimens must also include multiple vitamins, electrolytes, and trace elements. Potentially incompatible ions such as calcium and phosphate may be added to alternate infusate containers to avoid precipitation.

Special Populations

Pregnant Women:
There are no adequate data on use of 20% ProSol (Amino Acid Injection 20% w/v) in pregnant women. Healthcare professionals should carefully consider the potential risks and benefits for each specific patient before prescribing the product.

Animal reproduction studies have not been conducted with 20% ProSol (Amino Acid Injection 20% w/v). It is also not known whether 20% ProSol (Amino Acid Injection 20% w/v) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. 20% ProSol ™ (Amino Acid) Injection 20% w/v) should be given to a pregnant woman only if clearly needed.

Nursing Women:
There are no adequate data on use of 20% ProSol (Amino Acid Injection 20% w/v) in lactating women. Healthcare professionals should carefully consider the potential risks and benefits for each specific patient before prescribing the product.

Pediatrics:
There have been no studies performed by Baxter Healthcare Corporation in the pediatric population.

Hyperamonemia is of special significance in newborns and infants. In some patients this may indicate the presence of a congenital disorder or amino acid metabolism or hepatic insufficiency (see Endocrine and Metabolism). Blood ammonia should be measured frequently in newborns and infants to detect hyperammonemia, which may indicate the presence of a congenital abnormality of amino acid metabolism (see **Endocrine and Metabolism**). Should symptoms of hyperammonemia develop, administration should be discontinued and the patient's clinical status re-assessed.

Geriatrics:
In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.

Monitoring and Laboratory Tests
Monitoring should be appropriate to the patient's clinical situation and condition, and should include determinations of water and electrolyte balance, blood glucose, serum electrolytes, serum creatinine, BUN, liver and kidney function, bilirubin, serum osmolarity, blood ammonia, serum protein, acid/base balance, hematocrit, WBC, urinary glucose, and blood cultures when necessary.

When 20% ProSol (Amino Acid Injection 20% w/v) is combined with electrolytes, caution should be exercised against volume overload, particularly in patients with congestive heart failure, renal failure, edema, adrenal hyperactivity, acid base imbalance and those receiving diuretics or anti-hypertensive therapy. Serum electrolytes should be monitored daily.

ADVERSE REACTIONS

Adverse Drug Reaction Overview
Adverse reaction information is based on post-marketing experiences with parenteral amino acid products.

Post-Market Adverse Drug Reactions
Adverse reactions reported with parenteral amino acid products include:

IMMUNE SYSTEM DISORDERS:

- Anaphylactic/anaphylactoid reactions, including skin, gastrointestinal and severe circulatory (shock) and respiratory manifestations as well as other hypersensitivity/infusion reactions, including pyrexia, chills, hypotension, hypertension, arthralgia, myalgia, urticaria/rash, pruritus, erythema, and headache

METABOLISM AND NUTRITION DISORDERS:
- Hyperammonemia

RENAL AND URINARY DISORDERS:
- Azotemia

VASCULAR DISORDERS:
- Pulmonary vascular precipitates

Adverse reactions reported with parenteral nutrition to which the amino acid component may play a causal or contributory role include:

HEPATOBILIARY DISORDERS:
- Hepatic failure, Hepatic cirrhosis, Hepatic fibrosis, Cholestasis, Hepatic steatosis, Blood bilirubin increased, Hepatic enzyme increased; Cholecystitis, Cholelithiasis

GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS:
- Infusion site thrombophlebitis; Venous irritation (infusion site phlebitis, pain, erythema, warmth, swelling, induration)

DRUG INTERACTIONS

Overview
No interaction studies have been performed by Baxter Healthcare Corporation with 20% ProSol (Amino Acid Injection 20% w/v).

Drug-Drug Interactions
Caution must be exercised in administering these injections to patients receiving corticosteroids or corticotrophin.

Because of its antianabolic activity concurrent administration of tetracycline may reduce the protein-sparing effect of infused amino acids.

DOSAGE AND ADMINISTRATION

ProSol product is a pharmacy bulk package, and not for direct infusion. The high osmolarity of these products precludes direct administration due to potential phlebitic complications (see **DOSAGE FORMS, COMPOSITION AND PACKAGING, Composition**).

Dosing Considerations

Administration of ProSol as a Component of Parental Nutrition Therapy
Infusion of hypertonic nutrient injections into a peripheral vein may result in vein irritation, vein damage, and thrombosis.

Any unused portion of 20% ProSol (Amino Acid Injection 20% w/v) should be discarded and should not be used for subsequent admixing.

Recommended Dose and Dosage Adjustment

Electrolyte supplementation may be indicated according to the clinical needs of the patient. The total daily dose of these solutions depends on the patient's metabolic requirements and clinical response. The determination of nitrogen balance and accurate daily body weight, corrected for fluid balance, are probably the best means of assessing individual nitrogen requirements.

Recommended Dietary Allowances* of protein range from approximately 0.75 g/kg of body weight for adults to 1.68 g/kg for infants. It must be recognized, however, that protein as well as caloric requirements in traumatized or malnourished patients may be increased substantially. Daily amino acid doses of approximately 1.0 to 1.5 g/kg of body weight for adults and 2 to 3 g/kg of body weight for infants with adequate calories are generally sufficient to satisfy protein needs and promote positive nitrogen balance.

*Food and Nutrition Board National Academy of Sciences - National Research Council (Revised 1989).

As indicated on an individual basis, vitamins and trace elements and other components (including dextrose and lipids) can be added to the parenteral nutrition regimen to prevent deficiencies and complications from developing (see SPECIAL HANDLING INSTRUCTIONS).

Fat emulsion coadministration should be considered when prolonged parenteral nutrition is required in order to prevent essential fatty acid deficiency (EFAD).

Missed Dose

In the event of a missed dose, the infusion should be restarted at the recommended dose and flow rate. Doses should NOT be doubled.

Administration

The flow should start at a low rate and should be increased gradually. The flow rate must be adjusted taking into account the dose being administered, the daily volume intake, and the duration of the infusion.

Initiation and termination of infusions of TPN fluids must be gradual to permit adjustment of endogenous insulin release.

Central Vein Infusion

In unstressed adult patients with no unusual nitrogen losses, a minimum dosage of 0.1 gram nitrogen (3mL of 20% ProSol (Amino Acid Injection 20% w/v) plus 4.4 grams (15 calories) of dextrose/fat emulsion per kilogram of body weight per day is required to achieve nitrogen balance and weight stability. For patients stressed by surgery, trauma or sepsis, and those with unusual nitrogen losses, the dosage required for maintenance may be as high as 0.3 to 0.4 grams

of nitrogen (9.4 to 12.5 mL of 20% ProSol (Amino Acid Injection 20% w/v) per kilogram of body weight per day, with proportionate increases in non-protein calories. Periodic assessment of nitrogen balance of the individual patient is the best indicator of proper dosage. Use of an infusion pump is advisable to maintain a steady infusion rate during central venous infusion.

Administration by central venous catheter should be used only by those familiar with this technique and its complications.

Peripheral Infusion

The osmolarity of a specific an infusion solution must be taken into account when peripheral administration is considered. The osmolarity of an IV final solution administrated administered via peripheral vein should be below 900 mOsm/L. Osmolarity of 20% ProSol (Amino Acid Injection 20% w/v) exceeds this level (see **DOSAGE FORMS, COMPOSITION AND PACKAGING**). Therefore, for patients who require parenteral nutrition and in whom the central vein route is not indicated, the solution should be diluted accordingly and then infused by peripheral vein. Sterile water for injection or sterile dextrose solution for injection with low concentration of dextrose may be used for dilution.

In patients for whom central vein catheterization is not advisable, appropriate admixtures made by adequate dilution of 20% ProSol (Amino Acid Injection 20% w/v) can be administered by peripheral vein. If infused simultaneously, fat emulsion will provide a dilution effect upon the osmolarity, as well.

A sample TPN mixture of Baxter products is as follows (Typical Adult TPN Formula):

Solution	Volume	Final Solution	Protein	Calories
ProSol 20%	250 mL	5%	50g	200
Dextrose 70%	357 mL	25%		850
Sterile Water for Injection	393 mL			
Total	1000 mL			

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Use of a final filter is recommended during administration. For administration of parenteral solutions without lipids a 0.22 micron filter should be used. If lipid is also administered then a 1.2 micron filter should be used.

Instructions for Use and Handling, and Disposal

Confirm the integrity of the container. Use only if the container is not damaged and if the solution is clear, colorless or slightly yellow.

To Open:

1. Do not remove unit from overwrap until ready for use.
2. Remove the protective overpouch.
3. Check for leaks.

Preparation for Admixing

1. The Pharmacy Bulk Package is to be used only in a suitable aseptic work area.
2. Suspend container.
3. Remove plastic protector from port.
4. Attach a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents. Refer to complete directions accompanying device.
5. Viaflex® containers should not be written on directly since ink migration has not been investigated. Affix accompanying label for date and time of entry.

Administration of the infusion:

- For single use only.
- Do not reconnect any partially used container.
- Do not connect containers in series in order to avoid air embolism due to possible residual air contained in the primary container.

This Injection is for compounding only, not for direct infusion.

Once container closure has been penetrated, withdrawal of contents should be completed within 4 hours.

Additives

Additives may be incompatible.

Do not add other medicinal products or substances without first confirming their compatibility and the stability of the resulting preparation.

Excess addition of calcium and phosphate, especially in the form of mineral salts, may result in the formation of calcium phosphate precipitates which could lead to serious adverse reactions (see WARNINGS AND PRECAUTIONS, Respiratory and ADVERSE REACTIONS).

Discard the solution/emulsion if precipitates occur at any stage of the preparation for IV infusion of the product.

When compounding admixtures, use aseptic technique. Mix thoroughly. Do not store any unused portion of 20% ProSol (Amino Acid Injection 20% w/v).

OVERDOSAGE

For management of a suspected drug overdose, contact the regional Poison Control Centre.

In the event of inappropriate administration (overdose, and/or infusion rate higher than recommended), hyperammonemia, hypervolemia, electrolyte disturbances, acidosis and/or azotemia may occur and result in severe or fatal consequences. In such situations, the infusion must be stopped immediately. If medically appropriate, further intervention may be indicated to prevent clinical complications. See **WARNINGS AND PRECAUTIONS**.

There is no specific antidote for overdose. Emergency procedures should include appropriate corrective measures.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

20% ProSol (Amino Acid Injection 20% w/v) when mixed with caloric source (such as dextrose and or fat emulsion) electrolytes, vitamins, and minerals administered parenterally (central IV or peripheral IV) will provide biologically utilizable source for protein synthesis.

Pharmacodynamics

There have been no pharmacodynamic studies performed by Baxter Healthcare Corporation.

Pharmacokinetics

There have been no pharmacokinetic studies performed by Baxter Healthcare Corporation.

Special Populations and Conditions

There have been no clinical pharmacology studies performed by Baxter Healthcare Corporation in special populations and conditions.

STORAGE AND STABILITY

Store between 15 - 25°C. Protect from light.

After initial entry, maintain contents at room temperature (25°C).

Any admixture storage should be under refrigeration and limited to a brief period of time, preferably less than 24 hours.

Extemporaneously prepared solutions should be used promptly after mixing.

DOSAGE FORMS, COMPOSITION AND PACKAGING

20% ProSol (Amino Acid Injection 20% w/v) is a sterile, clear, nonpyrogenic, hypertonic solution of essential and nonessential amino acids. A Pharmacy Bulk Package, available in 500 mL, 1000 mL, and 2000 mL, is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion.

The Viaflex® plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146® Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period,(e.g. di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million). The studies in tissue culture and animals did not reveal safety concern.

Availability
20% ProSol (Amino Acid Injection 20% w/v) is available in Viaflex plastic Pharmacy Bulk Package containers as follows:

500 mL
1000 mL
2000 mL

Composition:
20% ProSol (Amino Acid Injection 20% w/v) is a sterile, non-pyrogenic solution of amino acids in water for injection USP.

Each 100 mL of 20% ProSol (Amino Acid Injection 20% w/v) contains:

Essential Amino Acids	
L-Valine	1.44 g
L-Histidine	1.18 g
L-Isoleucine	1.08 g
L-Leucine	1.08 g
L-Phenylalanine	1.00 g
L-Threonine	0.980 g
L-Lysine[1]	0.957 g
L-Methionine	0.760 g
L-Tryptophan	0.320 g

Non-Essential Amino Acids	
L-Alanine	2.76 g
Glycine	2.06 g
L-Arginine	1.96 g
L-Proline	1.34 g
L-Glutamic acid	1.02 g
L-Serine	1.02 g
L-Aspartic acid	0.600 g
L-Tyrosine	0.050 g

(pH adjusted with glacial acetic acid)

Total Amino Acids	20.0 g
Total Nitrogen	3.21 g
pH	6.0 (5.5 to 6.5)

Anion profiles per liter (balanced by ions from amino acids)	
Acetate from Lysine Acetate and glacial acetic acid	140 mEq
Osmolarity (Calc.)	1835 mOsmol/L

[1] One gram equivalent Lysine is equal to 1.41 grams Lysine Acetate

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Essential Amino Acids
L-Histidine, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L Phenylalanine, L-Threonine, L-Tryptophan, L-Valine

Non-Essential Amino Acids
L-Alanine, L-Arginine, L-Aspartic Acid, L-Glutamic Acid, Glycine, L-Proline, L-Tyrosine, L-Serine

Proper Name Chemical Name	**Molecular Formula and Molecular Mass**	**Structural Formula**	**Physicochemical Properties**
L-Alanine (S)-2-aminopropionic acid	$C_3H_7NO_2$ 89.09		White or almost white crystalline powder or colourless crystals, freely soluble in water, very slightly soluble in alcohol.
L-Arginine (2S)-2-amino-5-guanidinopentanoic acid	$C_6H_{14}N_4O_2$ 174.20		White or almost white crystalline powder or colourless crystals, freely soluble in water, very slightly soluble in alcohol.
L-Aspartic Acid (2S)-2-aminobutanedioic acid	$C_4H_7NO_4$ 133.10		White or almost white crystalline powder or colourless crystals, slightly soluble in water, practically insoluble in alcohol. It dissolves in dilute mineral acids and in dilute solutions of alkali hydroxides.
L-Glutamic Acid (2S)-2-aminopentanedioic acid	$C_5H_9NO_4$ 147.13		White crystalline powder or colourless crystals, freely soluble in boiling water, slightly soluble in cold water, practically insoluble in acetic acid, in acetone and in alcohol.
Glycine Aminoacetic acid	$C_2H_5NO_2$ 75.07		White or almost white crystalline powder, freely soluble in water, very slightly soluble in alcohol.

L-Histidine (S)-2-amino-1H-imidazole-4-propionic acid	$C_6H_9N_3O_2$ 155.15		White or almost white crystalline powder or colourless crystals, soluble in water, very slightly soluble in ethanol (96%).
L-Isoleucine (2S, 3S)-2-amino-3-methylpentanoic acid	$C_6H_{13}NO_2$ 131.17		White or almost white crystalline powder or flakes, sparingly soluble in water, slightly soluble in alcohol. It dissolves in dilute mineral acids and in dilute solutions of alkali hydroxides.
L-Leucine (2S)-2-amino-4-methylpentanoic acid	$C_6H_{13}NO_2$ 131.17		White or almost white crystalline powder or shiny flakes, sparingly soluble in water, practically insoluble in alcohol. It dissolves in dilute mineral acids and in dilute solutions of alkali hydroxides.
L-Lysine (S)-2,6-diaminohexanoic acid monohydrate	$C_6H_{14}N_2O_2 \cdot H_2O$ 164.21		White or almost white crystalline powder or colourless crystals, freely soluble in water, very slightly soluble in ethanol (96%).
L-Methionine (2S)-2-amino-4-(methylsulfanyl) butanoic acid	$C_5H_{11}NO_2S$ 149.21		White or almost white crystalline powder or colourless crystals, soluble in water, very slightly soluble in ethanol.
L-Phenylalanine (2S)-2-amino-3-phenylpropanoic acid	$C_9H_{11}NO_2$ 165.19		White or almost white crystalline powder or shiny, white flakes, sparingly soluble in water, very slightly soluble in alcohol. It dissolves in dilute mineral acids and in dilute solutions of alkali hydroxides.
L-Proline (S)-2-pyrrolidinecarboxylic acid	$C_5H_9NO_2$ 115.13		White or almost white crystalline powder or colourless crystals, very soluble in water, freely soluble in alcohol.
L-Serine (S)-2-amino-3-hydroxypropionic acid	$C_3H_7NO_3$ 105.09		White or almost white crystalline powder or colourless crystals, freely soluble in water, practically insoluble in alcohol.

L-Threonine (2S, 3R)-2-amino-3-hydroxybutanoic acid	$C_4H_9NO_3$ 119.12		White crystalline powder or colourless crystals, soluble in water, practically insoluble in ethanol.
L-Tryptophan (2S)-2-amino-3-(indol-3-yl)propanoic acid	$C_{11}H_{12}N_2O_2$ 204.23		White or almost white crystalline or amorphous powder, sparingly soluble in water, slightly soluble in alcohol. It dissolves in dilute mineral acids and in dilute solutions of alkali hydroxides.
L-Tyrosine (S)-2-amino-3-(4-hydroxyphenyl) propionic acid	$C_9H_{11}NO_3$ 181.19		White crystalline powder or colourless crystals, very slightly soluble in water, practically insoluble in alcohol. It dissolves in dilute mineral acids and in dilute solutions of alkali hydroxides.
L-Valine (2S)-2-amino-3-methylbutanoic acid	$C_5H_{11}NO_2$ 117.15		White or almost white crystalline powder or colourless crystals, soluble in water, very slightly soluble in ethanol.

CLINICAL TRIALS

There have been no clinical trials of this product performed by Baxter Healthcare Corporation.

DETAILED PHARMACOLOGY

There have been no pharmacology studies performed by Baxter Healthcare Corporation.

TOXICOLOGY

There have been no pharmacology studies performed by Baxter Healthcare Corporation.

REFERENCES

1. ASPEN Board of Directors. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN 2002; 26:1SA-138SA.

2. Anker SD, Laviano A, Filippatos G, John M, Paccagnella A, Ponikowski P, et al. ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. Clin Nutr 2009; 28:455–60.

3. Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher Z, Muscaritoli M, et al. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin Nutr 2009; 28:445–54.

4. Braga M, Ljungqvist O, Soeters P, Fearon K, Weimann A, Bozzetti F. ESPEN Guidelines on Parenteral Nutrition: surgery. Clin Nutr 2009; 28:378-86.

5. Cano et al. ESPEN Guidelines on Parenteral Nutrition: adult renal failure. Clin Nutr 2009; 28(4):401-414.

6. Gianotti et al., ESPEN Guidelines on Parenteral Nutrition: pancreas. Clin Nutr 2009; 28:428-435.

7. Koletzko B, Goulet O, Hunt J, Krohn K, Shamir R. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric Research (ESPR). J Pediatr Gastroenterol Nutr 2005; 41(Suppl 2):S1-87.

8. Pittiruti M, Hamilton H, Biffi R, MacFie J, Pertkiewicz M. ESPEN Guidelines on Parenteral Nutrition: central venous catheters (access, care, diagnosis and therapy of complications). Clin Nutr 2009; 28(1):365–77.

9. Plauth M, Cabré E, Campillo B, Kondrup J, Marchesini G, Schütz T, et al. ESPEN Guidelines on Parenteral Nutrition: hepatology. Clin Nutr 2009; 28(4):436-44.

10. Singer P, Berger M, Van den Berghe G, Biolo G, Calder P, Forbes A, et al. ESPEN Guidelines on Parenteral Nutrition: intensive care. Clin Nutr 2009; 28:387–400

11. Staun M, Pironi L, Bozzetti F, Baxter J, Forbes A, Joly F, et al. ESPEN Guidelines on Parenteral Nutrition: home parenteral nutrition. Clin Nutr 2009; 28:467–79.

12. Van Gossum A, Cabre E, Hebuterne X, Jeppesen P, Krznaric Z, Messing B, et al. ESPEN Guidelines on Parenteral Nutrition: gastroenterology. Clin Nutr 2009; 28:415-27.

PART III: CONSUMER INFORMATION

20% ProSol
(Amino Acid Injection 20% w/v)

This leaflet is part III of a three-part "Product Monograph" published when 20% ProSol (Amino Acid Injection 20% w/v) are approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about the product. Contact your healthcare professional if you have any questions.

ABOUT THIS MEDICATION

What the medication is used for:
20% ProSol (Amino Acid Injection 20% w/v) when administered with a source of energy is used as a source of amino acid nutrition in patients where:
(1) the digestive tract cannot or should not be used.
(2) absorption of protein in the stomach or intestine is impaired, or
(3) the needs for protein are greatly increased, as with extensive burns

What it does:
The use of 20% ProSol product is a way to ensure that patients who are unable to eat get an adequate intake of energy, nitrogen and other nutrients, and helps to treat or prevent malnutrition.

When it should not be used:
20% ProSol (Amino Acid Injection 20% w/v) should not be used in the following populations/situations:

- You are allergic to any of the ingredients (see **What the medicinal ingredients are and What the nonmedical are)**
- Your body has problems processing certain amino acids and these amino acids are included in ProSol product.
- You have liver failure or coma resulting from liver failure

What the medicinal ingredients are :

Ingredients (g)	Per 100mL
L-Alanine	2.76 g
L-Arginine	1.96 g
L-Aspartic Acid,	0.600 g
L-Glutamic Acid	1.02 g
Glycine	2.06 g
L-Histidine	1.18 g
L-Isoleucine	1.08 g
L-Leucine	1.08 g
L-Lysine	0.957 g
L-Methionine	0.760 g
L-Phenylalanine	1.00 g
L-Proline	1.34 g
L-Serine	1.02 g
L-Threonine	0.980 g
L-Tryptophan	0.320 g
L-Tyrosine	0.050 g
L-Valine	1.44 g

What the nonmedicinal ingredients are:
Glacial acetic acid (for pH adjustment), nitrogen, and water for injection.

What dosage forms it comes in:

- 20% ProSol (Amino Acid Injection 20% w/v) is a sterile, clear, solution of amino acids. It is supplied in a bag.
- 20% ProSol (Amino Acid Injection 20% w/v) is intended for use in pharmacy preparation programs and should **only be used** for the preparation of solutions for intravenous infusion, used to provide nutrition through a tube into a vein when normal feeding by mouth is not possible or suitable.
- your healthcare professional can tailor the infusion to your particular needs

WARNINGS AND PRECAUTIONS

BEFORE you use 20% ProSol (Amino Acid Injection 20% w/v), talk to your healthcare professional if:

- You are allergic to any ingredients. (See **What the medicinal ingredients are** and **What the nonmedicinal ingredients are**).
- You suffer from metabolic acidosis (when the blood is excessively acid)
- You have kidney or liver problems
- You are taking any other medicines on a regular basis
- You are taking calcium-containing intravenous solutions
- You are pregnant or intend to become pregnant
- You are breastfeeding or intend to breastfeed
- You have pulmonary edema (collection of fluid into the lung tissue)
- You have heart failure
- You have fluid overload (too much water in your body)

In all cases, your healthcare professional will base his/her decision to treat you or your child on factors such as age, weight and clinical condition, together with the results of any tests. Always be sure to check with your healthcare professional if anything about your condition changes.

In newborns and infants, your healthcare professional will measure blood ammonia frequently to check for the presence of a congenital abnormality of amino acid metabolism.

Your healthcare professional will need to monitor how you are doing while you are on this intravenous nutritive supplement. This means that you will need to have laboratory tests done on a routine basis.

INTERACTIONS WITH THIS MEDICATION

Drugs that may interact with 20% ProSol (Amino Acid Injection 20% w/v) include:

- No drug interaction studies have been performed with 20% ProSol (Amino Acid Injection 20% w/v).
- Let your healthcare professional know if you are receiving corticosteroids or corticotropin.
- Do not give tetracycline at the same time with 20% ProSol (Amino Acid Injection 20% w/v) as it may interfere with the effects of the amino acids
- 20% ProSol (Amino Acid Injection 20% w/v) must not be administered at the same time with blood through the same tubing with blood
- Do not give calcium at the same time as 20% ProSol (Amino Acid Injection 20% w/v) as particles may form which may lead to serious adverse reactions.

PROPER USE OF THIS MEDICATION

Usual dose:
20% ProSol (Amino Acid Injection 20% w/v) product is in pharmacy bulk package and are not for direct infusion. Your healthcare professional will reconstitute the products so they can be administered safely.

Your healthcare professional will tailor the infusion to your particular needs based on your age and body weight. Your healthcare professional will ensure that you are getting sufficient calories so that the amino acids from 20% ProSol (Amino Acid Injection 20% w/v) product will be absorbed. Your healthcare professional will also specify a flow rate corresponding to your needs and medical condition.

Overdose:
If your dose is too high or is infused too quickly, the amino acid content may make your blood too acidic. Giving too high a volume may cause fluid overload.
To prevent these events occurring, your healthcare professional will regularly monitor your condition and test your blood and urine parameters.

In case you feel you have been administered too much ProSol product, contact your healthcare practitioner (e.g. healthcare professional), hospital emergency department or the regional poison control centre, even if there are no symptoms.

Missed Dose:
If you feel a dose has been missed contact your attending healthcare professional.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

If you notice any changes in the way you feel during or after the treatment, tell your healthcare professional or another member of your medical team immediately.

The tests your healthcare professional will perform while you are taking the intravenous nutritive supplement should reduce the risk of side effects.

Side effects which have been reported with injectable nutrition products may include symptoms of an allergic reaction, such as fever or chills, shivering, skin rashes, severe headache or breathing difficulties. If you experience any of these symptoms, contact your attending healthcare professional immediately.

Other side effects which have been reported with injectable nutrition products may include rapid heart beat, sweating, nausea, vomiting, abdominal swelling, pain on the right side of your belly area (liver).

If any side effect gets serious, or if you notice any side effect not listed in this leaflet, please tell your healthcare professional or a member of your medical team right away.

Occasional reddening and stinging may occur at the point where the tubing enters the body. If this occurs, tell your healthcare professional or nurse immediately.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM				
Symptom / effect		**Talk with your doctor or pharmacist**		**Stop the infusion and contact your doctor (or healthcare professional)**
		Only if severe	**In all cases**	
Uncommon*	**Allergic reactions with symptoms such as fever or chills, shivering, skin rashes, breathing difficulties, severe headache**			√

* Side effects that have been reported with injectable nutrition products.

This is not a complete list of side effects. For any unexpected effects while taking 20% ProSol (Amino Acid Injection 20% w/v), contact your healthcare professional.

HOW TO STORE IT

The heatlhcare professional will store the 20% ProSol (Amino Acid Injection 20% w/v) at temperatures between 15°C and 25°C, and protected from light.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- **Report online at www.healthcanada.gc.ca/medeffect**
- **Call toll-free at 1-866-234-2345**
- **Complete a Canada Vigilance Reporting Form and:**
  - **Fax toll-free to 1-866-678-6789, or**
  - **Mail to: Canada Vigilance Program**
    Health Canada
    Postal Locator 0701E
    Ottawa, Ontario
    K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be obtained by contacting the sponsor, Baxter Corporation, at 1-888-719-9955.

This leaflet was prepared by Baxter Corporation, Mississauga, Ontario L5N 0C2, Canada.

Baxter, ProSol and Viaflex are registered trademarks of Baxter International Inc.

Last revised: September 3, 2015